Background:
Hairy cell leukemia (HCL) is a rare indolent B-cell neoplasm associated with cytopenias and increased susceptibility to infections. Standard first-line therapies, particularly purine analogues, achieve high remission rates but induce prolonged immunosuppression, including neutropenia and T-cell lymphopenia. Data on the incidence, timing, risk factors, and clinical outcomes of Invasive Fungal Diseases (IFD) in HCL patients remain limited and are largely restricted to case reports and small series.
This project focuses specifically on cases of IFD occurring during or after treatment of HCL, and every case — even a single one — is a valuable contribution to this rare entity.
Inclusion criteria:
- Diagnosis of hairy cell leukemia
- Documented invasive fungal disease
- Prior or ongoing treatment for HCL
- Availability of sufficient clinical data
Exclusion criteria:
- Incomplete or missing key data
- Uncertain diagnosis of fungal disease
- Patients without HCL diagnosis
Documentation is retrospective and anonymized. There is no direct patient intevention. For more information and participation, please contact Dr. Jill Papendick.
Downloads: